| Year |
Citation |
Score |
| 2022 |
Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, Wilson D, Wilson K, Brooijmans N, Kim J, Özen A, Perola E, Hsieh J, Brown V, Fetalvero K, et al. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry. PMID 35838760 DOI: 10.1021/acs.jmedchem.2c00704 |
0.647 |
|
| 2018 |
Rahal R, Maynard M, Hu W, Brubaker J, Cao Q, Kim JL, Sheets MP, Wilson DP, Wilson KJ, DiPietro L, Fleming P, LaBranche TP, Wolf B, Guzi T, Lengauer C, et al. Abstract B151: BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B151 |
0.309 |
|
| 2017 |
Siu T, Brubaker J, Fuller P, Torres L, Zeng H, Close J, Mampreian DM, Shi F, Liu D, Fradera X, Johnson K, Bays N, Kadic E, He F, Goldenblatt P, et al. The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious JAK1 Selective Inhibitor with Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry. PMID 29156136 DOI: 10.1021/Acs.Jmedchem.7B01135 |
0.338 |
|
| 2016 |
Rahal R, Evans EK, Hu W, Maynard M, Fleming P, DiPietro L, Kim JL, Sheets MP, Wilson DP, Wilson KJ, Stransky N, Brubaker JD, Guzi T, Kohl NE, Lengauer C. Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors Cancer Research. 76: 2641-2641. DOI: 10.1158/1538-7445.Am2016-2641 |
0.334 |
|
| 2015 |
Lim J, Altman MD, Baker J, Brubaker JD, Chen H, Chen Y, Fischmann T, Gibeau C, Kleinschek MA, Leccese E, Lesburg C, Maclean JK, Moy LY, Mulrooney EF, Presland J, et al. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4. Acs Medicinal Chemistry Letters. 6: 683-8. PMID 26101574 DOI: 10.1021/Acsmedchemlett.5B00107 |
0.358 |
|
| 2010 |
Hamzik PJ, Brubaker JD. Reactions of oxetan-3-tert-butylsulfinimine for the preparation of substituted 3-aminooxetanes. Organic Letters. 12: 1116-9. PMID 20141162 DOI: 10.1021/Ol100119E |
0.455 |
|
| 2008 |
Sun C, Wang Q, Brubaker JD, Wright PM, Lerner CD, Noson K, Charest M, Siegel DR, Wang YM, Myers AG. A robust platform for the synthesis of new tetracycline antibiotics. Journal of the American Chemical Society. 130: 17913-27. PMID 19053822 DOI: 10.1021/Ja806629E |
0.507 |
|
| 2008 |
Bailey WF, Salgaonkar PD, Brubaker JD, Sharma V. Preparation of the isomeric azaindoline family by intramolecular carbolithiation. Organic Letters. 10: 1071-4. PMID 18271595 DOI: 10.1021/Ol702862D |
0.327 |
|
| 2007 |
Brubaker JD, Myers AG. A practical, enantioselective synthetic route to a key precursor to the tetracycline antibiotics. Organic Letters. 9: 3523-5. PMID 17691796 DOI: 10.1021/Ol071377D |
0.61 |
|
| 2005 |
Charest MG, Lerner CD, Brubaker JD, Siegel DR, Myers AG. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science (New York, N.Y.). 308: 395-8. PMID 15831754 DOI: 10.1126/Science.1109755 |
0.622 |
|
| 2004 |
O'Donnell CJ, Singer RA, Brubaker JD, McKinley JD. A general route to the synthesis of 1,5-methano- and 1,5-ethano- 2,3,4,5-tetrahydro-1H-3-benzazepines. The Journal of Organic Chemistry. 69: 5756-9. PMID 15307752 DOI: 10.1021/Jo049122Q |
0.376 |
|
| Show low-probability matches. |